Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $270.00

Palvella Therapeutics (NASDAQ:PVLA) had its price objective increased by HC Wainwright from $255.00 to $270.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

PVLA has been the topic of a number of other research reports. Oppenheimer reissued an “outperform” rating and issued a $200.00 target price on shares of Palvella Therapeutics in a report on Monday, December 15th. Chardan Capital restated a “buy” rating and set a $210.00 price target on shares of Palvella Therapeutics in a research note on Monday, March 16th. Canaccord Genuity Group upped their price target on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Stifel Nicolaus set a $250.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Palvella Therapeutics has an average rating of “Moderate Buy” and an average price target of $195.93.

Palvella Therapeutics Price Performance

PVLA stock opened at $117.61 on Tuesday. The company has a market cap of $1.39 billion, a P/E ratio of -44.72 and a beta of -0.30. Palvella Therapeutics has a 1 year low of $18.23 and a 1 year high of $151.18. The stock’s fifty day moving average price is $104.27 and its 200-day moving average price is $89.95.

Insider Buying and Selling

In related news, Director Elaine J. Heron purchased 2,400 shares of Palvella Therapeutics stock in a transaction on Friday, February 27th. The stock was acquired at an average price of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the transaction, the director directly owned 47,812 shares in the company, valued at $5,976,500. This represents a 5.28% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The SEC filing for this sale provides additional information. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Invesco Ltd. grew its stake in shares of Palvella Therapeutics by 11.6% during the 4th quarter. Invesco Ltd. now owns 54,273 shares of the company’s stock valued at $5,681,000 after acquiring an additional 5,663 shares during the period. XTX Topco Ltd bought a new stake in Palvella Therapeutics during the 4th quarter worth approximately $429,000. Virtus Investment Advisers LLC bought a new stake in Palvella Therapeutics during the 4th quarter worth approximately $282,000. Superstring Capital Management LP purchased a new position in Palvella Therapeutics during the fourth quarter valued at approximately $2,666,000. Finally, Suvretta Capital Management LLC lifted its holdings in Palvella Therapeutics by 8.5% during the fourth quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after purchasing an additional 70,000 shares in the last quarter. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.